Antiphospholipid syndrome in 2014

More clinical manifestations, novel pathogenic players and emerging biomarkers

Pier L. Meroni, Cecilia B. Chighizola, Francesca Rovelli, Maria Gerosa

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

The clinical spectrum of the anti-phospholipid syndrome (APS) is not limited to vascular thrombosis or miscarriages but includes additional manifestations that cannot be explained solely by a thrombophilic state. Anti-cardiolipin, anti-beta2 glycoprotein I (anti-β2GPI) and lupus anticoagulant (LA) assays are not only the formal diagnostic and classification laboratory tools but also parameters to stratify the risk to develop the clinical manifestations of the syndrome. In particular, anti-β2GPI antibodies reacting with an immunodominant epitope on domain I of the molecule were reported as the prevalent specificity in APS patients, correlating with a more aggressive clinical picture. Several laboratory assays to improve the diagnostic and predictive power of the standard tests have been proposed. Plates coated with the phosphatidylserine-prothrombin complex for detecting antibodies represent a promising laboratory tool correlating with LA and with clinical manifestations. Anti-phospholipid antibodies can be found in patients with full-blown APS, in those with thrombotic events or obstetric complications only or in asymptomatic carriers. An inflammatory second hit is required to increase the presence of β2GPI in vascular tissues, eventually triggering thrombosis. Post-transcriptional modifications of circulating β2GPI, different epitope specificities or diverse anti-β2GPI antibody-induced cell signaling have all been suggested to affect the clinical manifestations and/or to modulate their occurrence.

Original languageEnglish
Article number209
JournalArthritis Research and Therapy
Volume16
Issue number2
DOIs
Publication statusPublished - Apr 23 2014

Fingerprint

beta 2-Glycoprotein I
Antiphospholipid Syndrome
Lupus Coagulation Inhibitor
Biomarkers
Blood Vessels
Antibodies
Thrombosis
Immunodominant Epitopes
Cardiolipins
Phosphatidylserines
Prothrombin
Spontaneous Abortion
Obstetrics
Epitopes
Anti-Idiotypic Antibodies
Phospholipids

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Antiphospholipid syndrome in 2014 : More clinical manifestations, novel pathogenic players and emerging biomarkers. / Meroni, Pier L.; Chighizola, Cecilia B.; Rovelli, Francesca; Gerosa, Maria.

In: Arthritis Research and Therapy, Vol. 16, No. 2, 209, 23.04.2014.

Research output: Contribution to journalArticle

@article{2a0a4c7c4f1043eba440cb936e2952f1,
title = "Antiphospholipid syndrome in 2014: More clinical manifestations, novel pathogenic players and emerging biomarkers",
abstract = "The clinical spectrum of the anti-phospholipid syndrome (APS) is not limited to vascular thrombosis or miscarriages but includes additional manifestations that cannot be explained solely by a thrombophilic state. Anti-cardiolipin, anti-beta2 glycoprotein I (anti-β2GPI) and lupus anticoagulant (LA) assays are not only the formal diagnostic and classification laboratory tools but also parameters to stratify the risk to develop the clinical manifestations of the syndrome. In particular, anti-β2GPI antibodies reacting with an immunodominant epitope on domain I of the molecule were reported as the prevalent specificity in APS patients, correlating with a more aggressive clinical picture. Several laboratory assays to improve the diagnostic and predictive power of the standard tests have been proposed. Plates coated with the phosphatidylserine-prothrombin complex for detecting antibodies represent a promising laboratory tool correlating with LA and with clinical manifestations. Anti-phospholipid antibodies can be found in patients with full-blown APS, in those with thrombotic events or obstetric complications only or in asymptomatic carriers. An inflammatory second hit is required to increase the presence of β2GPI in vascular tissues, eventually triggering thrombosis. Post-transcriptional modifications of circulating β2GPI, different epitope specificities or diverse anti-β2GPI antibody-induced cell signaling have all been suggested to affect the clinical manifestations and/or to modulate their occurrence.",
author = "Meroni, {Pier L.} and Chighizola, {Cecilia B.} and Francesca Rovelli and Maria Gerosa",
year = "2014",
month = "4",
day = "23",
doi = "10.1186/ar4549",
language = "English",
volume = "16",
journal = "Arthritis Research and Therapy",
issn = "1478-6354",
publisher = "BioMed Central",
number = "2",

}

TY - JOUR

T1 - Antiphospholipid syndrome in 2014

T2 - More clinical manifestations, novel pathogenic players and emerging biomarkers

AU - Meroni, Pier L.

AU - Chighizola, Cecilia B.

AU - Rovelli, Francesca

AU - Gerosa, Maria

PY - 2014/4/23

Y1 - 2014/4/23

N2 - The clinical spectrum of the anti-phospholipid syndrome (APS) is not limited to vascular thrombosis or miscarriages but includes additional manifestations that cannot be explained solely by a thrombophilic state. Anti-cardiolipin, anti-beta2 glycoprotein I (anti-β2GPI) and lupus anticoagulant (LA) assays are not only the formal diagnostic and classification laboratory tools but also parameters to stratify the risk to develop the clinical manifestations of the syndrome. In particular, anti-β2GPI antibodies reacting with an immunodominant epitope on domain I of the molecule were reported as the prevalent specificity in APS patients, correlating with a more aggressive clinical picture. Several laboratory assays to improve the diagnostic and predictive power of the standard tests have been proposed. Plates coated with the phosphatidylserine-prothrombin complex for detecting antibodies represent a promising laboratory tool correlating with LA and with clinical manifestations. Anti-phospholipid antibodies can be found in patients with full-blown APS, in those with thrombotic events or obstetric complications only or in asymptomatic carriers. An inflammatory second hit is required to increase the presence of β2GPI in vascular tissues, eventually triggering thrombosis. Post-transcriptional modifications of circulating β2GPI, different epitope specificities or diverse anti-β2GPI antibody-induced cell signaling have all been suggested to affect the clinical manifestations and/or to modulate their occurrence.

AB - The clinical spectrum of the anti-phospholipid syndrome (APS) is not limited to vascular thrombosis or miscarriages but includes additional manifestations that cannot be explained solely by a thrombophilic state. Anti-cardiolipin, anti-beta2 glycoprotein I (anti-β2GPI) and lupus anticoagulant (LA) assays are not only the formal diagnostic and classification laboratory tools but also parameters to stratify the risk to develop the clinical manifestations of the syndrome. In particular, anti-β2GPI antibodies reacting with an immunodominant epitope on domain I of the molecule were reported as the prevalent specificity in APS patients, correlating with a more aggressive clinical picture. Several laboratory assays to improve the diagnostic and predictive power of the standard tests have been proposed. Plates coated with the phosphatidylserine-prothrombin complex for detecting antibodies represent a promising laboratory tool correlating with LA and with clinical manifestations. Anti-phospholipid antibodies can be found in patients with full-blown APS, in those with thrombotic events or obstetric complications only or in asymptomatic carriers. An inflammatory second hit is required to increase the presence of β2GPI in vascular tissues, eventually triggering thrombosis. Post-transcriptional modifications of circulating β2GPI, different epitope specificities or diverse anti-β2GPI antibody-induced cell signaling have all been suggested to affect the clinical manifestations and/or to modulate their occurrence.

UR - http://www.scopus.com/inward/record.url?scp=84899102723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899102723&partnerID=8YFLogxK

U2 - 10.1186/ar4549

DO - 10.1186/ar4549

M3 - Article

VL - 16

JO - Arthritis Research and Therapy

JF - Arthritis Research and Therapy

SN - 1478-6354

IS - 2

M1 - 209

ER -